This is a paid press release. Contact the press release distributor directly with any enquiries.
Artificial Intelligence (AI)-Powered Pathology Analysis System Market Global Report 2026
Rising cancer cases and pathologist shortages drive AI pathology adoption, creating opportunities in cloud diagnostics, telepathology, precision oncology, automated imaging and decision support.
Artificial Intelligence (AI)-Powered Pathology Analysis System Market
Dublin, Sept. 01, 2026 (GLOBE NEWSWIRE) — The “Artificial Intelligence (AI)-Powered Pathology Analysis System Market Global Report 2026” report has been added to ResearchAndMarkets.com’s offering.
The artificial intelligence (AI)-powered pathology analysis system market size has grown rapidly in recent years. It will grow from $66.06 billion in 2025 to $78.02 billion in 2026 at a compound annual growth rate (CAGR) of 18.1%. The growth in the historic period can be attributed to rising prevalence of chronic and infectious diseases increasing diagnostic demand, growth in hospital and laboratory infrastructure globally, increasing adoption of digital imaging in pathology workflows, shortage of skilled pathologists in many regions, development of basic computer-assisted diagnostic tools in healthcare.
The artificial intelligence (AI)-powered pathology analysis system market size is expected to see rapid growth in the next few years. It will grow to $153.02 billion in 2030 at a compound annual growth rate (CAGR) of 18.3%. The growth in the forecast period can be attributed to advancement in ai and deep learning algorithms for medical image analysis, expansion of precision medicine and genomics-driven diagnostics, increasing adoption of cloud-based healthcare data ecosystems, growth in telepathology and remote diagnostic services, rising investment in healthcare digital transformation and automation. Major trends in the forecast period include increasing adoption of ai-powered digital pathology platforms for high-accuracy disease detection, growing use of cloud-based pathology data management systems for remote diagnostics, rising integration of deep learning models in histopathology image interpretation, expansion of automated slide scanning and digital workflow solutions in diagnostic laboratories, increasing demand for ai-assisted clinical decision support systems in oncology and disease screening.
The increasing cancer incidence is expected to propel the growth of the artificial intelligence (AI)-powered pathology analysis system market going forward. Cancer refers to a disease characterized by the uncontrolled multiplication of abnormal cells that can invade and spread to other parts of the body, originating in various tissues and organs and classified according to the cell or tissue type from which it develops. Cancer incidence is increasing due to rising life expectancy, as the risk of developing cancer grows with age. Artificial intelligence (AI)-powered pathology analysis systems support cancer diagnosis by automatically analyzing biopsy and tissue samples to detect, classify, and quantify cancerous cells, enabling faster and more accurate diagnosis while supporting early cancer detection. For instance, in August 2024, according to Macmillan Cancer Support, a UK-based organization, more than 3 million people in the UK were living with cancer in 2024, with this figure projected to increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the increasing cancer incidence is driving the growth of the artificial intelligence (AI)-powered pathology analysis system market.
Key companies operating in the artificial intelligence (AI)-powered pathology analysis system market are focusing on developing advanced solutions, such as AI-driven cancer detection and diagnostic support platforms, to enhance pathology workflow efficiency, improve diagnostic accuracy, accelerate clinical decision-making, and address the growing shortage of pathologists in healthcare systems. AI-driven cancer detection and diagnostic support platforms are software systems that use artificial intelligence to analyze medical data and images, helping healthcare professionals identify potential cancerous abnormalities and make more informed diagnostic decisions. For example, in April 2025, Paige.AI Inc., a US-based healthcare technology company, received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its AI application Paige PanCancer Detect, which is designed to assist pathologists in identifying cancerous regions across multiple tissue and organ types. The system uses advanced artificial intelligence to detect both common and rare cancer variants, helping improve diagnostic accuracy and reduce turnaround time in pathology workflows. It aims to address the increasing global shortage of pathologists by streamlining case screening and supporting faster clinical decision-making. This recognition highlights the growing role of AI in precision oncology and strengthens Paige’s position in developing regulatory-approved digital pathology solutions for improved cancer detection and patient care.
In May 2026, Grundium Oy, a Finland-based medical technology company, acquired Visiopharm A/S for an undisclosed amount. Through this acquisition, Grundium advanced its strategy of building a broader digital and computational pathology platform by integrating Visiopharm’s AI-driven precision pathology software with its advanced imaging technology. The combined capabilities established a comprehensive end-to-end pathology solution for diagnostic laboratories, biopharmaceutical development, and research applications. Visiopharm A/S is a Denmark-based company specializing in AI-powered pathology analysis software and related services.
Major companies operating in the artificial intelligence (AI)-powered pathology analysis system market are F. Hoffmann-La Roche Ltd.; Danaher Corporation; Koninklijke Philips N.V.; Hologic Inc.; Tempus AI Inc.; Owkin Inc.; OptraSCAN Inc.; Proscia Inc.; Tribun Health; 3DHISTECH Ltd.; Visiopharm A/S; Indica Labs Inc.; Ibex Medical Analytics Ltd.; Mindpeak GmbH; Aiosyn; DeepBio Inc.; AIRA Matrix Pvt. Ltd.; Aiforia Technologies Plc.; Lunit Inc.; Google Cloud.
North America was the largest region in the artificial intelligence (AI)-powered pathology analysis system market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-powered pathology analysis system market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI)-powered pathology analysis system market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The artificial intelligence (AI)-powered pathology analysis system market consists of revenues earned by entities by providing services such as automated image analysis, digital pathology integration, AI-based diagnostic support, pattern recognition, predictive analytics, and clinical decision support systems. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI)-powered pathology analysis system market also includes sales of whole-slide scanners, fluorescence slide scanners, automated microscopy systems, digital pathology workstations, and medical-grade display monitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The artificial intelligence (AI)-powered pathology analysis system market research report is one of a series of new reports that provides artificial intelligence (AI)-powered pathology analysis system market statistics, including artificial intelligence (AI)-powered pathology analysis system industry global market size, regional shares, competitors with a artificial intelligence (AI)-powered pathology analysis system market share, detailed artificial intelligence (AI)-powered pathology analysis system market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI)-powered pathology analysis system industry. This artificial intelligence (AI)-powered pathology analysis system market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Executive Summary:
Artificial Intelligence (AI)-Powered Pathology Analysis System Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses artificial intelligence (ai)-powered pathology analysis system market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
